Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sefaxersen in Primary IgA Nephropathy
NCT05797610Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2023
- Primary completion
- May 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 21
01
Overview
A Phase 3 trial of sefaxersen in IgA nephropathy (IgAN), sponsored by Roche. Started Aug 2023; status: active, not recruiting.
02
Drugs
sefaxersen
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05797610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797610.